scispace - formally typeset
T

Todd R. Golub

Researcher at Harvard University

Publications -  454
Citations -  234100

Todd R. Golub is an academic researcher from Harvard University. The author has contributed to research in topics: Cancer & Gene expression profiling. The author has an hindex of 164, co-authored 422 publications receiving 201457 citations. Previous affiliations of Todd R. Golub include Rush University Medical Center & Boston Children's Hospital.

Papers
More filters

Initial genome sequencing and analysis of multiple myeloma

TL;DR: In this paper, a massively parallel sequencing of 38 tumour genomes and their comparison to matched normal DNAs was reported, and several new and unexpected oncogenic mechanisms were suggested by the pattern of somatic mutation across the data set.
Journal ArticleDOI

Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes

TL;DR: A comprehensive genetic analysis of 304 primary DLBCLs identified low-frequency alterations, captured recurrent mutations, somatic copy number alterations, and structural variants, and defined coordinate signatures in patients with available outcome data to provide a roadmap for an actionableDLBCL classification.
Journal ArticleDOI

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma

TL;DR: High-resolution copy number data with transcriptional profiles are integrated and identified the immunoregulatory genes, PD-L1 andPD-L2, as key targets at the 9p24.1 amplification peak in HL and MLBCL cell lines, defining the PD-1 pathway and JAK2 as complementary rational therapeutic targets.
Journal ArticleDOI

Increased Expression of Genes Converting Adrenal Androgens to Testosterone in Androgen-Independent Prostate Cancer

TL;DR: Enhanced intracellular conversion of adrenal androgens to testosterone and dihydrotestosterone is a mechanism by which prostate cancer cells adapt to androgen deprivation and suggest new therapeutic targets.